Ftse Mib
34.467,67
0,00%
DAX
18.691,32
0,05%
S&P 500
5.267,84
-0,74%
NASDAQ
16.736,03
-0,39%
Bitcoin
67.147,67
-1,14%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Amneal Pharmaceuticals Holding Co (AMRX) Amneal Pharmaceuticals Holding Co (AMRX) Notizie

AMRX

Amneal Pharmaceuticals (AMRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:AMRX
DataOraFonteTitoloSimboloCompagnia
22/05/202422:05Business WireAmneal to Participate at Upcoming Investor ConferenceNYSE:AMRXAmneal Pharmaceuticals Holding Co
22/05/202422:05Business WireAmneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of CaliforniaNYSE:AMRXAmneal Pharmaceuticals Holding Co
16/05/202421:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
14/05/202422:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
07/05/202422:18Edgar (US Regulatory)Form 8-K - Current reportNYSE:AMRXAmneal Pharmaceuticals Holding Co
03/05/202412:00Business WireAmneal Reports First Quarter 2024 Financial ResultsNYSE:AMRXAmneal Pharmaceuticals Holding Co
24/04/202414:00Business WireAmneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid OverdoseNYSE:AMRXAmneal Pharmaceuticals Holding Co
16/04/202414:00Business WireAmneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable MedicineNYSE:AMRXAmneal Pharmaceuticals Holding Co
10/04/202414:00Business WireAmneal to Report First Quarter 2024 Results on May 3, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
28/03/202421:05Business WireAmneal to Ring the Nasdaq Closing Bell on April 2, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
25/03/202421:05Business WireAmneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic SuspensionNYSE:AMRXAmneal Pharmaceuticals Holding Co
22/03/202413:01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNYSE:AMRXAmneal Pharmaceuticals Holding Co
22/03/202413:01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNYSE:AMRXAmneal Pharmaceuticals Holding Co
01/03/202412:00Business WireAmneal Reports Fourth Quarter and Full Year 2023 Financial ResultsNYSE:AMRXAmneal Pharmaceuticals Holding Co
27/02/202414:00Business WireAmneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203NYSE:AMRXAmneal Pharmaceuticals Holding Co
08/02/202422:05GlobeNewswire Inc.Amneal Announces Complete Response Resubmission for IPX203 New Drug ApplicationNYSE:AMRXAmneal Pharmaceuticals Holding Co
31/01/202422:05Business WireAmneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
10/01/202414:00Business WireAmneal Launches Complex Generic Fluorometholone Ophthalmic SuspensionNYSE:AMRXAmneal Pharmaceuticals Holding Co
04/01/202422:05Business WireAmneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023NYSE:AMRXAmneal Pharmaceuticals Holding Co
26/12/202322:10Edgar (US Regulatory)Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
26/12/202322:05Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NYSE:AMRXAmneal Pharmaceuticals Holding Co
21/12/202314:00Business WireAmneal to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:AMRXAmneal Pharmaceuticals Holding Co
15/12/202322:06Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NYSE:AMRXAmneal Pharmaceuticals Holding Co
15/12/202322:05Business WireAmneal Announces Move to NasdaqNYSE:AMRXAmneal Pharmaceuticals Holding Co
07/12/202314:00Business WireAmneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)NYSE:AMRXAmneal Pharmaceuticals Holding Co
01/12/202322:15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NYSE:AMRXAmneal Pharmaceuticals Holding Co
01/12/202322:15Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NYSE:AMRXAmneal Pharmaceuticals Holding Co
01/12/202314:00Business WireAmneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel CapsulesNYSE:AMRXAmneal Pharmaceuticals Holding Co
20/11/202312:07Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NYSE:AMRXAmneal Pharmaceuticals Holding Co
15/11/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNYSE:AMRXAmneal Pharmaceuticals Holding Co
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:AMRX

La tua Cronologia

USOTC
FRTAY
Freenet (PK)
BIT
F19162
Vontobel Financial Produ...
EU
XS0130092793
Ned Watersch 01/32 Mtn
AQSE
PHC.GB
Plant Health
NASDAQ
CYAND
USOTC
JROOF
Jericho Energy Ventures (PK)
USOTC
TRUFF
Red Light Holland (QB)
AQSE
HMAF.GB
HSBC MSCI AC Far East Ex...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network